ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
February 21, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces FDA Clearance and first-in-human cases using 2.2 Software with integrated Maestro Brain Modeling, and publication in NeuroImage
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
January 24, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
First successful procedure with ClearPoint Prism Neuro Laser Therapy System and Neuro Navigation System by Kaleida Health in Buffalo.
ClearPoint Neuro tillkännager sin första EU MDR-certifiering och godkännande att skicka produkter till Europa
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (”Företaget”), ett globalt företag inom medicinteknik och cell- och genterapi som erbjuder exakt...
ClearPoint Neuro gibt erste erfolgreiche EU-MDR-Zertifizierung und Genehmigung zur Lieferung von Produkten nach Europa bekannt
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Kalifornien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (das „Unternehmen“), ein weltweit tätiges Unternehmen im Bereich Medizinprodukte sowie Zell- und...
ClearPoint Neuro annonce être arrivé pour la première fois au terme du processus de certification de conformité au Règlement européen MDR et obtenu l’autorisation d’expédier son produit en Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californie, 22 janv. 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq : CLPT (la « Société »), une entreprise internationale spécialisée dans les dispositifs médicaux, les...
ClearPoint Neuro annoncerer første EU MDR certificeringssucces og godkendelse til at sende produkt til Europa
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Californien, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) ("Virksomheden"), en global enhed, celle- og genterapi-virksomhed, der tilbyder præcis navigation...
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
January 22, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.
ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System
January 16, 2024 08:00 ET
|
ClearPoint Neuro, Inc.
ClearPoint Neuro received 510(k) clearance for SmartFrame OR, first product in company history designed for the operating room instead of the MRI suite.
ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue
January 08, 2024 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
ClearPoint Neuro Reports Third Quarter 2023 Results
November 09, 2023 16:05 ET
|
ClearPoint Neuro, Inc.
SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...